ESMO 2023 | Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wt refractory mCRC

Rechallenge with anti-EGFR inhibitors in metastatic colorectal cancer (mCRC) patients with refractory RAS/BRAF wild-type circulating tumor DNA (ctDNA) has shown clinical efficacy, although evidence is largely from small studies. Davide Ciardiello, MD, University of Campania Luigi Vanvitelli, Naples, Italy, discusses findings from a pooled analysis of individual patient data from CAVE (NCT04561336), VELO (NCT05468892), CRICKET (NCT02296203), and CHRONOS (NCT03227926) trials. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.